-  EBITDA up significantly to USD 12.2. EBIT up by approximately 300% to USD 5.0 million; Net Income from continuing operations.

launches by SHL.
"Cardio Sen'C" the first personal cellular- digital 12 lead ECG transmitter

improvement in financial results and operating cash flow
SHL's revenues for the third quarter increased to USD 21.6 million from USD 20.9 million in Q3 of 2005 with revenues for the quarter from the telemedicine segment showing an increase of 6% to USD 15.4 million from USD 14.5 million in Q3 of 2005.

with St. Jude Medical GmbH. Serious rhythm dysfunctions can cause sudden death which can be prevented by implanted cardioverter-defibrillators. The ICD is smaller than a matchbox and when recognizing rhythm disorders delivers an electric shock, bringing the heart beat back to the right rhythm

SHL's revenues for the second quarter amounted to USD 22.1 million with EBITDA amounting to USD 2.4 million and EBIT to USD 0.5 million.

in line with expectations with revenues reaching USD 23.0 million and EBITDA of USD 1.8 million.

of the Advisory Board of PHTS,SHL's German subsidiaryErez Alroy, Co-CEO of SHL Telemedicine comments: "We are delighted by Mr Schleifer's commitment for our pioneering activities in the German telemedicine market.

Voluntary change in accounting policy. In 2005, revenues were USD 99.0 million compared to USD 107.7 in 2004. Revenues from the telemedicine services segment amounted to USD 58.4 million (2004: USD 59.4 million), while revenues from the medical services segment declined to USD 40.6 million (2004: USD 48.3 million) due to the impact of the divesture of Bikurofe and the
weak performance of the medical imaging centers in the US.

Full Year 2005 ResultsMedia & Analyst ConferenceZurich, 30 March 2006